Addex Therapeutics Ltd
ADXN
$7.90
$0.202.60%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -43.76% | -44.18% | |||
| Total Revenue | 40.59% | -44.18% | |||
| Cost of Revenue | 0.42% | 63.71% | |||
| Gross Profit | 6.96% | -153.81% | |||
| SG&A Expenses | -0.22% | 11.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.03% | 23.79% | |||
| Operating Income | 2.05% | -31.75% | |||
| Income Before Tax | 16.97% | -44.94% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 16.97% | -44.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.66% | -36.23% | |||
| EBIT | 2.05% | -31.75% | |||
| EBITDA | 1.78% | -31.83% | |||
| EPS Basic | 21.17% | -32.93% | |||
| Normalized Basic EPS | 26.35% | -42.31% | |||
| EPS Diluted | 21.17% | -32.93% | |||
| Normalized Diluted EPS | 26.35% | -42.31% | |||
| Average Basic Shares Outstanding | 12.09% | 2.21% | |||
| Average Diluted Shares Outstanding | 12.09% | 2.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||